Eli Lilly reports Phase 3 trial win for oral GLP-1 in diabetes
Eli Lilly reported the first Phase 3 data for its oral GLP-1 orforglipron Thursday morning, saying the drug succeeded in a type 2 diabetes trial. The drug hit the primary endpoint of lowering A1C by …
Daily Pill May Work as Well as Ozempic for Weight Loss and Blood Sugar
Clinical results of a GLP-1 in pill form showed safety and efficacy data similar to blockbuster injectable drugs.
Major weight loss pill breakthrough as medical trial sees people lose 16lbs
Lilly, which makes weight loss injections, unveils trial result showing Type 2 diabetes sufferers lost 8% of body weight taking GLP-1 drug in tablet form – and millions could soon get them
Daily Pill May Work as Well as Ozempic for Weight Loss and Blood Sugar – The New York Times
Daily Pill May Work as Well as Ozempic for Weight Loss and Blood Sugar The New York Times Eli Lilly’s weight loss pill succeeds in first late-stage trial on diabetes patients CNBC Lilly’s oral GLP-1, orforglipron, demonstrated statistically significant efficacy results and a safety profile consistent with injectable GLP-1 medicines in successful Phase 3 trial Eli Lilly and […]
Lilly’s oral GLP-1, orforglipron, demonstrated statistically significant efficacy results and a …
Related Stocks: LLY,
Lilly’s First Pill for Diabetes, Weight Loss Shows Positive Study Results
The drug helped lower blood sugar and cut an average of 16 pounds The first GLP-1 weight-loss pill is a step closer to hitting the market. Eli Lilly said its experimental pill met its goals in a pivotal study, helping diabetes patients lower blood sugar—and even reduce weight, bringing an oral …
STAT+: Daily pill from Eli Lilly helps patients control blood sugar, lose weight, Phase 3 study shows
A daily pill from Eli Lilly helped patients with type 2 diabetes improve their blood sugar and shed weight, the company said Thursday, results that could propel the next-generation treatment onto the market. The drug, orforglipron, produced results that were nearly comparable to the benefits of available GLP-1 drugs, which are weekly injectable treatments. Companies […]
Eli Lilly jumps as oral GLP-1 drug succeeds in Phase 3 trial
Post Content
Lilly’s oral GLP-1 drug delivers Ozempic-like efficacy in phase 3 diabetes trial
Eli Lilly has met its goal of achieving semaglutide-like efficacy with an oral GLP-1 drug. The phase 3 study linked the oral GLP-1 drug orforglipron to similar reductions in blood glucose and body weight to Novo Nordisk’s injectable blockbuster, although the figures are down on Lilly’s midphase data.